Close Menu

This article has been updated with information from Thermo Fisher's earnings conference call.

NEW YORK  – Thermo Fisher Scientific on Wednesday morning reported a 10 percent year-over-year boost in second quarter revenues, driven by increased global demand for COVID-19-related products and services.

The results are in line with the Waltham, Massachusetts-based company's earlier prediction of 10 percent revenue growth for Q2.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.